Progress Report: Sri Lanka Clinical Trials Registry

SLCTR registration number: **SLCTR/2019/039**

Scientific title of trial: A randomised control trial to evaluate the impact of a clinical pharmacist on optimizing the quality use of medicines according to the Acute Coronary Syndrome (ACS) secondary prevention guidelines and medication adherence following discharge in patients with ACS

Date of commencement (enrolment of first participant): 29.11.2019

Progression: 6 months   1 year   2 years   3 years
                 At completion ⋆

1. Baseline data

Any changes to the trial design/ methodology/ protocol after commencement: None

Any changes to trial outcomes after commencement: None

2. Current status

Recruitment status: ~~pending/ recruiting/~~ recruitment complete: ~~follow up continuing/ recruitment complete:~~ follow up complete~~/ recruitment suspended / recruitment terminated~~

Number assessed for eligibility: 393

Number recruited and allocated/randomized:365

Number allocated/randomized to each intervention/arm (please edit as relevant):

      Arm 1: Control - 180

      Arm 2:Intervention - 185

Losses/exclusions after allocation/randomization (please edit as relevant):

      Arm 1:22 at last follow-up

      Arm 2:20 at last follow-up

3. Trial output

Date of trial completion ("last patient, last visit"):10.03.2022

Final sample size:323 at the time of final follow-up

Summary of Interim/Final data (if available):

A total of 365 patients were enrolled in the study and most of them were older male (55%, mean age 62.68 years). Both groups showed poor baseline medication adherence and DRPs were detected successfully in both groups. Most (60%) of the suggestions provided by the clinical pharmacists to resolve DRPs and optimize medications were accepted by the treating team. The discharge medication appropriateness of the intervention group was significantly higher compared to that of control group (p<0.0001). Medication adherence at six-months post discharge was improved considerably in the intervention group (by 49.3%) compared to that of control group (by 18.8%)

Abstract presentations of results at scientific meetings
Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).
A preliminary assessment of medication adherence and impact of clinical pharmacy interventions on medication optimisation in patients with acute coronary syndrome	**Bagyawantha NMY**, Gawarammana IB, Coombes ID, Mohamed F. *136th anniversary international medical congress 2023 organized by Sri Lanka Medical Association (SLMA),* Page No S178
Improvement of medication adherence and discharge medication appropriateness of patients diagnosed with acute coronary syndrome followed by clinical pharmacy interventions in a tertiary care hospital in Sri Lanka	**Bagyawantha NMY**, Coombes ID, Gawarammana I, Mohamed F. *81st FIP World Congress of Pharmacy and Pharmaceutical Sciences 2023,Brisbane, Australia, Pharmacy Education Journal,* DOI:10.46542/pe.2023.236.350423 Page No -380

Publications
Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)
Impact of a clinical pharmacist on optimising the quality use of medicines according to the acute coronary syndrome (ACS) secondary prevention guidelines and medication adherence following	Bagyawantha NMY, Coombes ID, Gawarammana I, *et al* Impact of a clinical pharmacist on optimising the quality use of medicines according to the acute coronary syndrome (ACS) secondary prevention guidelines and medication adherence following discharge in patients with ACS in Sri Lanka: a prospective non-randomised controlled trial study protocol,

discharge in patients with ACS in Sri Lanka: a prospective non-randomised controlled trial study protocol.	*BMJ Open* 2023;**13:**e059413. doi: 10.1136/bmjopen-2021-059413

N.M.Y. Bagyawantha

…………………………………………………………………..
Name and signature of Responsible Registrant/
Principal Investigator

Date: 24.01.2024